MCID: UTR043
MIFTS: 48

Uterine Sarcoma

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Uterine Sarcoma

MalaCards integrated aliases for Uterine Sarcoma:

Name: Uterine Sarcoma 53 55
Uterine Corpus Sarcoma 73
Sarcoma of the Uterus 53

Classifications:



Summaries for Uterine Sarcoma

MalaCards based summary : Uterine Sarcoma, also known as uterine corpus sarcoma, is related to rhabdoid cancer and leiomyosarcoma. An important gene associated with Uterine Sarcoma is ABCB1 (ATP Binding Cassette Subfamily B Member 1), and among its related pathways/superpathways are Glioma and Gastric cancer. The drugs Gemcitabine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 The uterine sarcomas form a group of malignant tumors that arises from the smooth muscle or connective... more...

Related Diseases for Uterine Sarcoma

Diseases related to Uterine Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Related Disease Score Top Affiliating Genes
1 rhabdoid cancer 30.3 DES SMARCB1 WT1
2 leiomyosarcoma 28.1 DES KIT MB MDM2 PDGFRB WT1
3 leiomyoma 27.8 CYP19A1 DES ESR1 KIT MME
4 adenosarcoma 27.2 DES ESR1 KIT MB MME
5 breast cancer 25.8 ABCB1 ABCC1 CCND2 CDK2 CYP19A1 ESR1
6 endometrial stromal sarcoma 25.7 CYP19A1 DES ESR1 KIT MB MME
7 sarcoma 10.9
8 testicular gonadoblastoma 10.8 KIT WT1
9 microsporidiosis 10.8 ABCB1 ABCC1
10 ovarian fibrothecoma 10.6 DES KIT
11 colchicine resistance 10.6 ABCB1 ABCC1
12 retroperitoneal sarcoma 10.6 MDM2 SMARCB1
13 ovarian small cell carcinoma 10.5 DES WT1
14 gallbladder sarcoma 10.5 DES KIT
15 proliferative fasciitis 10.5 MB SMARCB1
16 core binding factor acute myeloid leukemia 10.5 KIT MVP WT1
17 kidney rhabdoid cancer 10.4 MB SMARCB1 WT1
18 hypereosinophilic syndrome, idiopathic 10.4 KIT PDGFRB WT1
19 chronic eosinophilic leukemia 10.4 KIT PDGFRB WT1
20 spindle cell lipoma 10.4 DES MDM2
21 breast rhabdomyosarcoma 10.3 DES MB
22 epithelioid cell melanoma 10.3 MCAM WT1
23 giant cell myocarditis 10.3 DES MB
24 neurilemmoma 10.3 DES KIT SMARCB1
25 retinal cancer 10.3 CCND2 CDK2 MDM2
26 sensory system cancer 10.3 CCND2 CDK2 MDM2
27 malignant triton tumor 10.3 DES MB
28 botryoid rhabdomyosarcoma 10.3 DES MB
29 nervous system cancer 10.3 CDK2 MDM2 SMARCB1
30 desmoid tumor 10.3 KIT PDGFRB
31 sarcomatoid squamous cell skin carcinoma 10.3 KIT MB
32 cribriform carcinoma 10.3 ESR1 KIT
33 connective tissue cancer 10.2 KIT MDM2 SMARCB1
34 adenoid basal cell carcinoma 10.2 ESR1 KIT
35 spindle cell synovial sarcoma 10.2 KIT MB SMARCB1
36 uterine inversion 10.2
37 spindle cell rhabdomyosarcoma 10.2 DES MB
38 malignant peripheral nerve sheath tumor 10.2 KIT MDM2 SMARCB1
39 angiomyoma 10.2 CDK2 KIT MB
40 medullomyoblastoma 10.2 DES MB SMARCB1
41 myxosarcoma 10.1 ABCB1 MB MDM2
42 sclerosing liposarcoma 10.1 MB MDM2
43 embryonal sarcoma 10.1 DES KIT MDM2
44 dermatofibrosarcoma protuberans 10.1 DES KIT PDGFRB
45 benign metastasizing leiomyoma 10.1 CYP19A1 DES
46 spindle cell liposarcoma 10.1 KIT MDM2 SMARCB1 WT1
47 fibrosarcoma of bone 10.0 KIT MDM2 PDGFRB
48 inflammatory myofibroblastic tumor 10.0 DES KIT MDM2
49 sarcoma, synovial 10.0 DES KIT MDM2
50 smooth muscle tumor 10.0 DES ESR1 KIT

Graphical network of the top 20 diseases related to Uterine Sarcoma:



Diseases related to Uterine Sarcoma

Symptoms & Phenotypes for Uterine Sarcoma

GenomeRNAi Phenotypes related to Uterine Sarcoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00107-A-1 9.68 DCK
2 Decreased viability GR00221-A-1 9.68 KIT PDGFRB SMARCB1 DCK ESR1
3 Decreased viability GR00221-A-2 9.68 SMARCB1 DCK ESR1
4 Decreased viability GR00221-A-3 9.68 PDGFRB SMARCB1
5 Decreased viability GR00221-A-4 9.68 PDGFRB DCK ESR1
6 Decreased viability GR00240-S-1 9.68 DCK
7 Decreased viability GR00301-A 9.68 KIT
8 Decreased viability GR00342-S-1 9.68 PDGFRB
9 Decreased viability GR00381-A-1 9.68 SMARCB1
10 Decreased viability GR00402-S-2 9.68 PDGFRB SMARCB1 DCK ESR1 KIT
11 Decreased HPV16-GFP infection GR00350-A 9.26 ABCC1 DCK DES PGRMC1

MGI Mouse Phenotypes related to Uterine Sarcoma:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.38 ABCB1 CCND2 CDK2 CYP19A1 DES ESR1
2 behavior/neurological MP:0005386 10.35 ABCB1 CCND2 CYP19A1 DES ESR1 KIT
3 homeostasis/metabolism MP:0005376 10.35 ABCB1 ABCC1 CCND2 CDK2 CYP19A1 DES
4 hematopoietic system MP:0005397 10.34 PDGFRB SMARCB1 WT1 ABCB1 ABCC1 CCND2
5 cellular MP:0005384 10.3 CDK2 CYP19A1 DCK DES ESR1 KIT
6 immune system MP:0005387 10.3 SMARCB1 WT1 ABCB1 ABCC1 CCND2 CDK2
7 endocrine/exocrine gland MP:0005379 10.26 PDGFRB PGRMC1 WT1 ABCB1 CCND2 CDK2
8 growth/size/body region MP:0005378 10.25 ABCB1 CDK2 CYP19A1 ESR1 KIT MB
9 mortality/aging MP:0010768 10.18 ABCB1 ABCC1 CCND2 CDK2 DES ESR1
10 embryo MP:0005380 10.14 WT1 CDK2 ESR1 KIT MB MDM2
11 liver/biliary system MP:0005370 10.1 ABCB1 CCND2 CDK2 CYP19A1 ESR1 KIT
12 digestive/alimentary MP:0005381 10.09 ABCB1 CYP19A1 ESR1 KIT MDM2 PDGFRB
13 integument MP:0010771 10.03 CDK2 CYP19A1 ESR1 KIT MDM2 MME
14 muscle MP:0005369 10.02 CYP19A1 DES ESR1 KIT MB MDM2
15 nervous system MP:0003631 9.9 ABCC1 CCND2 CYP19A1 ESR1 KIT MDM2
16 neoplasm MP:0002006 9.73 CDK2 ESR1 KIT MDM2 SMARCB1 WT1
17 normal MP:0002873 9.56 DCK ESR1 KIT MDM2 MVP PDGFRB
18 reproductive system MP:0005389 9.36 ABCB1 CCND2 CDK2 CYP19A1 ESR1 KIT

Drugs & Therapeutics for Uterine Sarcoma

Drugs for Uterine Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
2
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
4
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
5
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
6
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Not Applicable 33069-62-4 36314
7
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
8
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
9
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
10
Mesna Approved, Investigational Phase 3 3375-50-6 598
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Cyproheptadine Approved Phase 3 129-03-3 2913
13
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
14
Bevacizumab Approved, Investigational Phase 3 216974-75-3
15
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
16
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
17 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
18
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
19 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Albumin-Bound Paclitaxel Phase 3,Phase 2,Not Applicable
21 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
22 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
23 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
24 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
25 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
26 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
27 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Liver Extracts Phase 3,Phase 1,Phase 2,Not Applicable
29 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
30 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
31 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
32 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
35 Analgesics Phase 3,Phase 2,Phase 1,Not Applicable
36 Central Nervous System Depressants Phase 3
37 Adjuvants, Anesthesia Phase 3
38 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
39 Mitogens Phase 3,Phase 2
40 Narcotics Phase 3
41 Analgesics, Opioid Phase 3
42 Anesthetics Phase 3
43 Anesthetics, General Phase 3
44 Anesthetics, Intravenous Phase 3
45 Endothelial Growth Factors Phase 3,Phase 2
46 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Gastrointestinal Agents Phase 3,Phase 2
48 Antibodies Phase 3,Phase 2
49 Immunoglobulins Phase 3,Phase 2
50 Antibodies, Monoclonal Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 121)
# Name Status NCT ID Phase Drugs
1 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
2 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
3 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
4 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
5 Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
6 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
9 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
10 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
11 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
12 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Active, not recruiting NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
13 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
14 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Active, not recruiting NCT01376349 Phase 3 prasterone
15 Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
16 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
17 Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma Unknown status NCT01303094 Phase 2 Trabectedin
18 Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers Unknown status NCT02052128 Phase 1, Phase 2 onapristone
19 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2 temozolomide;thalidomide
20 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
21 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
22 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
23 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
24 Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
25 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
26 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
27 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
28 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
29 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
30 Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Completed NCT01220609 Phase 2 Ixabepilone
31 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01168232 Phase 2 Ixabepilone
32 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
33 Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00031629 Phase 2 Docetaxel;Gemcitabine Hydrochloride
34 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
35 Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00025220 Phase 2 Thalidomide
36 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed NCT00112489 Phase 2 carboplatin;paclitaxel
37 Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Completed NCT00101127 Phase 2 docetaxel;gemcitabine hydrochloride
38 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Completed NCT00379145 Phase 2 trabectedin
39 Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00003778 Phase 2 dolastatin 10
40 Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer Completed NCT01764802 Phase 2
41 Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery Completed NCT01553539 Phase 2 therapeutic angiotensin-(1-7)
42 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Completed NCT01079832 Phase 2
43 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
44 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
45 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
46 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
47 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2 thalidomide
48 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
49 Chemotherapy in Treating Patients With Advanced Sarcoma Completed NCT00002526 Phase 2 doxorubicin hydrochloride;ifosfamide
50 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate

Search NIH Clinical Center for Uterine Sarcoma

Genetic Tests for Uterine Sarcoma

Anatomical Context for Uterine Sarcoma

MalaCards organs/tissues related to Uterine Sarcoma:

41
Uterus, Smooth Muscle, Lung, Brain, Bone, Endothelial, T Cells

Publications for Uterine Sarcoma

Articles related to Uterine Sarcoma:

(show top 50) (show all 314)
# Title Authors Year
1
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. ( 29553955 )
2018
2
Can the risks associated with uterine sarcoma morcellation really be prevented? Overview of the role of uterine morcellation in 2018. ( 29879489 )
2018
3
Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy. ( 29281902 )
2018
4
SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma. ( 29700418 )
2018
5
The impact of morcellation on survival outcomes of undiagnosed uterine sarcoma. ( 29892685 )
2018
6
RNA-sequencing identifies novel GREB1-NCOA2 fusion gene in a uterine sarcoma with the chromosomal translocation t(2;8)(p25;q13). ( 29218853 )
2018
7
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in seven patients with peritoneal sarcomatosis from uterine sarcoma. ( 29881584 )
2018
8
Rare case of undifferentiated uterine sarcoma with neuroectodermal differentiation and osteoclast-like giant cells. ( 29880181 )
2018
9
Clinical Characteristics Differentiating Uterine Sarcoma and Fibroids. ( 29398899 )
2018
10
Expression and prognostic value of lactate dehydrogenase-A and -D subunits in human uterine myoma and uterine sarcoma. ( 29620641 )
2018
11
Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. ( 29185261 )
2018
12
Efficacy of Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Treatment of Recurrent Uterine Sarcoma. ( 29975291 )
2018
13
Reducing the spread of occult uterine sarcoma at the time of minimally invasive gynecologic surgery. ( 29128980 )
2018
14
Uterine Sarcoma Presenting with Sepsis from <i>Clostridium perfringens</i> Endometritis in a Postmenopausal Woman. ( 29850320 )
2018
15
Utility of Clinical Parameters and Multiparametric MRI as Predictive Factors for Differentiating Uterine Sarcoma From Atypical Leiomyoma. ( 29422425 )
2018
16
Efficacy of PET/CT to exclude leiomyoma in patients with lesions suspicious for uterine sarcoma on MRI. ( 28805609 )
2017
17
Uterine sarcoma with ambiguous histomorphology: A case report. ( 28271093 )
2017
18
Cytotoxic effects of 15-deoxy-I912,14-prostaglandin J2 alone and in combination with dasatinib against uterine sarcoma in vitro. ( 28587364 )
2017
19
Undifferentiated Uterine Sarcoma: An Uncommon Case Report. ( 28511398 )
2017
20
18F-FDG/18F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma. ( 28186981 )
2017
21
Multi-institutional study of peritoneal sarcomatosis from uterine sarcoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. ( 28967566 )
2017
22
Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma. ( 28643014 )
2017
23
Undiagnosed Uterine Sarcomas Identified During Surgery for Presumed Leiomyoma at a National Tertiary Hospital in Thailand: A 10-Year Review. ( 28498251 )
2017
24
Unsuspected Uterine Sarcoma in an Urban Hospital: Does Surgical Approach Matter? ( 29061369 )
2017
25
Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment. ( 28174295 )
2017
26
Elevated levels of serum MiR-152 and miR-24 in uterine sarcoma: potential for inducing autophagy via SIRT1 and deacetylated LC3. ( 28929922 )
2017
27
A Multicentre Retrospective Review of Clinical Characteristics of Uterine Sarcoma. ( 28729098 )
2017
28
Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma. ( 28541635 )
2017
29
Uterine sarcoma - current perspectives. ( 28919822 )
2017
30
Does the patients age at cancer diagnosis affect microvessels density in uterine sarcoma tissues? ( 28397202 )
2017
31
Role of Lymphadenectomy for Uterine Sarcoma: A Meta-Analysis. ( 27668397 )
2017
32
Frequency of uterine sarcomas in patients admitted for uterine fibroid surgery. ( 28400352 )
2017
33
Pulmonary Metastasis of Undifferentiated Uterine Sarcoma Forming Fluid-Containing Cyst. ( 28862061 )
2017
34
Uterine epithelioid leiomyosarcoma with c-kit expression and YWHAE gene rearrangement: a case report of a diagnostic pitfall of uterine sarcoma. ( 28288693 )
2017
35
Establishment and characterization of uterine sarcoma and carcinosarcoma patient-derived xenograft models. ( 28625393 )
2017
36
Magnetic resonance imaging features of uterine sarcoma and mimickers. ( 28246921 )
2017
37
Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand. ( 27221849 )
2016
38
Uterine sarcoma Part I-Uterine leiomyosarcoma: The Topic Advisory Group systematic review. ( 27590365 )
2016
39
Uterine sarcoma part III-Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review. ( 27751406 )
2016
40
Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications. ( 26855091 )
2016
41
Uterine Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database. ( 27177280 )
2016
42
A uterus soaked in blood with low haemoglobin in a case of unrecognized uterine sarcoma. ( 27048123 )
2016
43
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy. ( 27208537 )
2016
44
Outcomes of uterine sarcoma found incidentally after uterus-preserving surgery for presumed benign disease. ( 27553655 )
2016
45
Uterine sarcoma Part II-Uterine endometrial stromal sarcoma: The TAG systematic review. ( 27590366 )
2016
46
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. ( 27012429 )
2016
47
Clinical Characteristics and Prognosis of Unexpected Uterine Sarcoma After Hysterectomy for Presumed Myoma With and Without Transvaginal Scalpel Morcellation. ( 26807642 )
2016
48
Correction: A Retrospective Analysis of the Impact of Myomectomy on Survival in Uterine Sarcoma. ( 27078148 )
2016
49
Uterine sarcoma vs adenocarcinoma: can MRI distinguish between them? ( 26617259 )
2016
50
Morcellation of undiagnosed uterine sarcoma: A critical review. ( 26672915 )
2016

Variations for Uterine Sarcoma

Expression for Uterine Sarcoma

Search GEO for disease gene expression data for Uterine Sarcoma.

Pathways for Uterine Sarcoma

Pathways related to Uterine Sarcoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.56 CCND2 CDK2 ESR1 MDM2 PDGFRB
2
Show member pathways
12.54 ABCB1 CDK2 ESR1 KIT SMARCB1
3 12.15 CCND2 CDK2 ESR1 KIT MDM2 PDGFRB
4 12.14 ABCB1 ABCC1 CYP19A1 MB PGRMC1
5 12.03 ABCB1 ABCC1 CCND2 MDM2 PDGFRB
6 11.89 CDK2 CYP19A1 ESR1 MDM2
7 11.78 CDK2 MDM2 PDGFRB
8 11.64 CDK2 DCK MDM2
9
Show member pathways
11.43 ABCB1 KIT PDGFRB
10 11.36 CDK2 MDM2 SMARCB1
11 11.19 CCND2 CDK2 MDM2
12 10.72 ABCB1 ABCC1
13 10.65 ABCB1 ABCC1
14 10.51 ABCB1 ABCC1
15 10.05 ABCB1 ABCC1 DCK
16 9.92 CYP19A1 ESR1

GO Terms for Uterine Sarcoma

Biological processes related to Uterine Sarcoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.85 CCND2 KIT MDM2 PDGFRB WT1
2 positive regulation of cell proliferation GO:0008284 9.8 CCND2 CDK2 KIT MDM2 PDGFRB
3 positive regulation of DNA binding transcription factor activity GO:0051091 9.7 ESR1 KIT SMARCB1
4 phosphatidylinositol phosphorylation GO:0046854 9.65 ESR1 KIT PDGFRB
5 cell chemotaxis GO:0060326 9.54 ABCC1 KIT PDGFRB
6 androgen metabolic process GO:0008209 9.51 CYP19A1 ESR1
7 uterus development GO:0060065 9.49 CYP19A1 ESR1
8 cellular response to estrogen stimulus GO:0071391 9.43 ESR1 MDM2
9 xenobiotic transport GO:0042908 9.32 ABCB1 ABCC1
10 metanephric mesenchyme development GO:0072075 9.26 PDGFRB WT1
11 male gonad development GO:0008584 9.26 ESR1 KIT PDGFRB WT1
12 metanephric S-shaped body morphogenesis GO:0072284 9.16 PDGFRB WT1
13 positive regulation of phospholipase C activity GO:0010863 8.8 ESR1 KIT PDGFRB

Molecular functions related to Uterine Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.7 ABCB1 ABCC1 CDK2 DCK KIT NAV2
2 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.13 ESR1 KIT PDGFRB
3 xenobiotic transmembrane transporting ATPase activity GO:0008559 8.62 ABCB1 ABCC1

Sources for Uterine Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....